Vermillion (VRML) Shares Surge 36% Amid Positive OVA1 Blood Test Data
Tweet
Share
E-mailGet Alerts VRML Hot Sheet
Join SI Premium – FREE
Shares of Vermillion (Nasdaq: VRML) have surged more than 36 percent in mid-day trade following the release of data on its OVA1 blood test which show the test detects ovarian cancer more accurately than the CA 125 method.
The stock last traded at $4.55.
Shares of Quest Diagnostics (NYSE: DGX), which offers the test, did not move much following the data release, however are at session highs. The stock is now up 1.4 percent to $57.80.
The stock last traded at $4.55.
Shares of Quest Diagnostics (NYSE: DGX), which offers the test, did not move much following the data release, however are at session highs. The stock is now up 1.4 percent to $57.80.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Home Depot expands executive roles, grants $500K in restricted stock
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
